Values of Cytokines and Tryptophan Metabolites over a 12 Weeks Time Course in Patients with Depression and Somatoform Disorder

키워드

참고문헌 (37)

1. Dantzer R, "Psychoneuroimmunology", pp.281~318 (2007), Academic Press
2. Leonard BE, "The concept of depression as a dysfunction of the immune system", Curr Immunol Rev, 6, pp.205~212 (2010)
3. Dowlati Y, "A meta-analysis of cytokines in major depression", Biol Psychiatry, 67, pp.446~457 (2010)
4. Howren MB, "Associations of depression with C-reactive protein, IL-1, and IL-6 : a meta-analysis", Psychosom Med, 71, pp.171~186 (2009)
5. Capuron L, "Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy", Mol Psychiatry, 7, pp.468~473 (2002)
6. Wichers MC, "IDO and interferon-alpha-induced depressive symptoms : a shift in hypothesis from tryptophan depletion to neurotoxicity", Mol Psychiatry, 10, pp.538~544 (2005)
7. Maes M, "The new ‘5-HT’ hypothesis of depression : cell-mediated immune activation induces indoleamine 2, 3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites(TRYCATs), both of which contribute to the onset of depression", Prog Neuropsychopharmacol Biol Psychiatry, 35, pp.702~721 (2011)
8. Seden Demirci, "The Serum Levels of Resistin and Its Relationship with Other Proinflammatory Cytokines in Patients with Alzheimer’s Disease", Clinical Psychopharmacology and Neuroscience, 15(1), pp.59~63 (2017), 대한정신약물학회[DOI]
9. Anderson G, "Biological phenotypes underpin the physio-somatic symptoms of somatization, depression, and chronic fatigue syndrome", Acta Psychiatr Scand, 129, pp.83~97 (2014)
10. Rief W, "Psychobiological differences between depression and somatization", J Psychosom Res, 68, pp.495~502 (2010)
11. Eyre H, "Neuroimmunological effects of physical exercise in depression", Brain Behav Immun, 26, pp.251~266 (2012)
12. Kang HJ, "Effects of interleukin-6, interleukin-18, and statin use, evaluated at acute stroke, on post-stroke depression during 1-year follow-up", Psychoneuroendocrinology, 72, pp.156~160 (2016)
13. Tully PJ, "The longitudinal association between inflammation and incident depressive symptoms in men : the effects of hs-CRP are independent of abdominal obesity and metabolic disturbances", Physiol Behav, 139, pp.328~335 (2015)
14. Euteneuer F, "Psychobiological aspects of somatization syndromes : contributions of inflammatory cytokines and neopterin", Psychiatry Res, 195, pp.60~65 (2012)
15. Euteneuer F, "Depression, cytokines and experimental pain : evidence for sex-related association patterns", J Affect Disord, 131, pp.143~149 (2011)
16. Wittchen HU, "Structured clinical interview for DSM-IV" (1997), Hogrefe Verlag
17. Hiller W, "Somatization in the population : from mild bodily misperceptions to disabling symptoms", Soc Psychiatry Psychiatr Epidemiol, 41, pp.704~712 (2006)
18. Rief W, "Classification of somatoform disorders", Am J Psychiatry, 163, pp.746~747 (2006)
19. Escobar JI, "Somatic symptom index (SSI): a new and abridged somatization construct. Prevalence and epidemiological correlates in two large community samples", J Nerv Ment Dis, 177, pp.140~146 (1989)
20. Rief W, "Toward empirically based criteria for the classification of somatoform disorders", J Psychosom Res, 46, pp.507~518 (1999)
21. Schmitt M, "Norms for the simplified Beck Depression Inventory(BDI-V)in a non-clinical population", Diagnostica, 52, pp.51~59 (2006)
22. Derogatis LR, "SCL-90-R: Administration, scoring and procedures manual" (1994), National Computer Systems
23. Pedrosa Gil F, "Alexithymia and interleukin variations in somatoform disorder", Neuroimmunomodulation, 14, pp.235~242 (2007)
24. Frey I, "[Freiburg Questionnaire of physical activity--development, evaluation and application", Soz Praventivmed, 44, pp.55~64 (1999)
25. Oades RD, "Attention-deficit hyperactivity disorder(ADHD)and glial integrity : an exploration of associations of cytokines and kynurenine metabolites with symptoms and attention", Behav Brain Funct, 6, pp.32~ (2010)
26. Perneger TV, "What’s wrong with Bonferroni adjustments", BMJ, 316, pp.1236~1238 (1998)
27. LaClair R, "Precision of biomarkers to define chronic inflammation in CKD", Am J Nephrol, 28, pp.808~812 (2008)
28. Kaplan RC, "Within-individual stability of obesity-related biomarkers among women", Cancer Epidemiol Biomarkers Prev, 16, pp.1291~1293 (2007)
29. Zalli A, "Low-grade inflammation predicts persistence of depressive symptoms", Psychopharmacology(Berl), 233, pp.1669~1678 (2016)
30. Maes M, "Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways", BMC Med, 10, pp.66~ (2012)
31. Dantzer R, "Inflammationassociated depression : from serotonin to kynurenine", Psychoneuroendocrinology, 36, pp.426~436 (2011)
32. Gabbay V, "The kynurenine pathway in adolescent depression : preliminary findings from a proton MR spectroscopy study", Prog Neuropsychopharmacol Biol Psychiatry, 34, pp.37~44 (2010)
33. Rothermundt M, "Different immune patterns in melancholic and non-melancholic major depression", Eur Arch Psychiatry Clin Neurosci, 251, pp.90~97 (2001)
34. Meier CA, "IL-1 receptor antagonist serum levels are increased in human obesity : a possible link to the resistance to leptin", J Clin Endocrinol Metab, 87, pp.1184~1188 (2002)
35. Marques-Vidal P, "Levels and determinants of inflammatory biomarkers in a Swiss population-based sample(CoLaus study)", PLoS One, 6, pp.e21002~ (2011)
36. Kwidzinski E, "IDO expression in the brain: a double- edged sword", J Mol Med (Berl), 85, pp.1351~1359 (2007)
37. Moylan S, "The neuroprogressive nature of major depressive disorder : pathways to disease evolution and resistance, and therapeutic implications", Mol Psychiatry, 18, pp.595~606 (2013)

관련 논문AI추천